Vnitr Lek 1993, 39(6):549-553

[Tiracizine in the treatment of ventricular arrhythmia (preliminary study)].

M Stejfa, K Zeman, L Groch, J Bytesník, R Krausová

I. interní klinika FN u sv. Anny v Brnĕ.

Tiracizine a new antiarrhythmic drug class Ia was tested in a open crossover study in a group of 46 patients with more than 2500 ventricular extrasystoles per 24 hours or with ventricular arrhythmias III or a higher Lown class. The authors revealed a statistically significant drop of ventricular extrasystoles and a significant reduction of arrhythmias class IV of Lown's classification with a general shift of arrhythmias to lower classes. Improvement by at least one class occurred in 63%, deterioration without clinical impact in 11%. The drug does not have a clinical effect on haemodynamics. Side-effects of an anticholinergic type were recorded in 13% and a toxic allergic exanthema was observed in 6.5%. Tiracizine extends the spectrum of membrane antiarrhythmic drugs. Its effectiveness is similar as that of propafenon.

Keywords: Anti-Arrhythmia Agents, adverse effects, ; Arrhythmias, Cardiac, drug therapy, ; Dibenzazepines, adverse effects, ; Female; Heart Ventricles; Humans; Male; Middle Aged; Propafenone, adverse effects,

Published: June 1, 1993  Show citation